David Goldstein

31.3k total citations · 4 hit papers
446 papers, 18.7k citations indexed

About

David Goldstein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, David Goldstein has authored 446 papers receiving a total of 18.7k indexed citations (citations by other indexed papers that have themselves been cited), including 281 papers in Oncology, 106 papers in Pulmonary and Respiratory Medicine and 71 papers in Cancer Research. Recurrent topics in David Goldstein's work include Pancreatic and Hepatic Oncology Research (118 papers), Cancer Treatment and Pharmacology (78 papers) and Cancer Genomics and Diagnostics (64 papers). David Goldstein is often cited by papers focused on Pancreatic and Hepatic Oncology Research (118 papers), Cancer Treatment and Pharmacology (78 papers) and Cancer Genomics and Diagnostics (64 papers). David Goldstein collaborates with scholars based in Australia, United States and Canada. David Goldstein's co-authors include Susanna B. Park, Michael Friedländer, Matthew C. Kiernan, Phyllis Butow, Arun V. Krishnan, Minoti V. Apte, Malcolm J. Moore, Jeremy S. Wilson, Romano C. Pirola and Cindy Lin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Personality and Social Psychology.

In The Last Decade

David Goldstein

431 papers receiving 18.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

2007 2.9k citations David Goldstein et al. profile →
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

2016 685 citations David Goldstein, Jenny Shannon et al. profile →
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

2013 558 citations Susanna B. Park, David Goldstein et al. profile →
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

2015 504 citations David Goldstein et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
David Goldstein	11.8k	3.9k	2.9k	2.8k	2.7k	446	18.7k
Phyllis A. Wingo	9.4k 0.8×	4.9k 1.3×	3.0k 1.0×	2.7k 1.0×	4.2k 1.5×	105	20.8k
Lynn A. G. Ries	13.0k 1.1×	6.6k 1.7×	3.7k 1.3×	3.6k 1.3×	4.1k 1.5×	81	26.7k
Alfred Rademaker	5.8k 0.5×	6.7k 1.7×	5.7k 2.0×	2.5k 0.9×	3.9k 1.4×	639	30.6k
John L. Hopper	9.5k 0.8×	4.3k 1.1×	2.2k 0.8×	4.6k 1.7×	7.0k 2.6×	769	32.6k
Benjamin F. Hankey	9.5k 0.8×	5.3k 1.4×	2.9k 1.0×	2.1k 0.8×	1.9k 0.7×	76	18.0k
Michael Friedländer	15.7k 1.3×	3.7k 1.0×	3.2k 1.1×	4.6k 1.6×	7.5k 2.7×	493	27.5k
Robert N. Anderson	7.1k 0.6×	3.5k 0.9×	2.0k 0.7×	2.0k 0.7×	2.8k 1.0×	118	19.5k
Dallas R. English	5.9k 0.5×	2.4k 0.6×	1.9k 0.7×	1.7k 0.6×	3.8k 1.4×	592	29.5k
Kathleen A. Cronin	9.6k 0.8×	3.9k 1.0×	1.7k 0.6×	3.9k 1.4×	2.6k 1.0×	118	17.5k
Kent A. Griffith	4.3k 0.4×	1.9k 0.5×	1.6k 0.6×	2.7k 1.0×	2.0k 0.7×	277	12.8k

Countries citing papers authored by David Goldstein

Since Specialization

Citations

This map shows the geographic impact of David Goldstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Goldstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Goldstein more than expected).

Fields of papers citing papers by David Goldstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Goldstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Goldstein. The network helps show where David Goldstein may publish in the future.

Co-authorship network of co-authors of David Goldstein

This figure shows the co-authorship network connecting the top 25 collaborators of David Goldstein. A scholar is included among the top collaborators of David Goldstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Goldstein. David Goldstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Tiffany, Hannah C. Timmins, Lisa G. Horvath, et al.. (2024). Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity. Journal of the National Comprehensive Cancer Network. 22(2). 108–116. 6 indexed citations

Li, Tiffany, Michelle Harrison, Sanjeev Kumar, et al.. (2024). Upper-limb dysfunction in cancer survivors with chemotherapy-induced peripheral neurotoxicity. Journal of the Neurological Sciences. 457. 122862–122862. 3 indexed citations

Li, Tiffany, Hui‐Ming Lin, Hannah C. Timmins, et al.. (2024). Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy. JCO Precision Oncology. 8(8). e2300690–e2300690. 1 indexed citations

Best, Megan, Nicci Bartley, Christine E. Napier, et al.. (2022). Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study. Supportive Care in Cancer. 30(10). 8201–8210. 4 indexed citations

Goldstein, David, Hannah C. Timmins, Tiffany Li, et al.. (2022). Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study. Journal of Translational Medicine. 20(1). 564–564. 6 indexed citations

Clifford, Briana K., Matthew D. Jones, David Simar, B. Benjamin, & David Goldstein. (2021). The effect of exercise intensity on exercise‐induced hypoalgesia in cancer survivors: A randomized crossover trial. Physiological Reports. 9(19). e15047–e15047. 4 indexed citations

Maharaj, Ashika, Sue Evans, John Zalcberg, et al.. (2020). Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework. PLoS ONE. 15(12). e0243312–e0243312. 3 indexed citations

Blinman, Prunella, Andrew Martin, Michael Jefford, et al.. (2020). Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. JNCI Cancer Spectrum. 5(1). 4 indexed citations

Best, Megan, Phyllis Butow, Chris Jacobs, et al.. (2020). Advanced cancer patient preferences for receiving molecular profiling results. Psycho-Oncology. 29(10). 1533–1539. 7 indexed citations

10.

Maharaj, Ashika, Sue Evans, John Zalcberg, et al.. (2020). Barriers and enablers to the implementation of multidisciplinary team meetings: a qualitative study using the theoretical domains framework. BMJ Quality & Safety. 30(10). 792–803. 16 indexed citations

11.

McNamara, Mairéad G., Andre Lopes, Harpreet Wasan, et al.. (2020). Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. Journal of Hepatology. 73(5). 1109–1117. 29 indexed citations

12.

Smit, Amelia K., Nicci Bartley, Megan Best, et al.. (2020). Family communication about genomic sequencing: A qualitative study with cancer patients and relatives. Patient Education and Counseling. 104(5). 944–952. 10 indexed citations

13.

Best, Megan, Nicci Bartley, Chris Jacobs, et al.. (2019). Patient perspectives on molecular tumor profiling: “Why wouldn’t you?”. BMC Cancer. 19(1). 753–753. 26 indexed citations

14.

Wan, Yi, et al.. (2018). Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. SHILAP Revista de lepidopterología. 1 indexed citations

15.

Beesley, Vanessa L., Monika Janda, David Goldstein, et al.. (2016). A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services.. The Sydney eScholarship Repository (The University of Sydney). 47 indexed citations

16.

Lim, Hui Jun, Xiaochun Wang, Philip Crowe, David Goldstein, & Jia‐Lin Yang. (2016). Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines. Anticancer Research. 36(11). 5765–5772. 23 indexed citations

17.

Xu, Zhihong, Alain Vonlaufen, Phoebe A. Phillips, et al.. (2010). Role of Pancreatic Stellate Cells in Pancreatic Cancer Metastasis. American Journal Of Pathology. 177(5). 2585–2596. 286 indexed citations

18.

Butow, Phyllis, Maurice Eisenbruch, David Goldstein, et al.. (2009). Abstract B32: Unmet needs in Chinese, Greek, and Arabic speaking cancer patients in Australia. Cancer Epidemiology and Prevention Biomarkers. 18. 4 indexed citations

19.

Apte, Minoti V., Phoebe A. Phillips, Nicole Santucci, et al.. (2004). Desmoplastic Reaction in Pancreatic Cancer. Pancreas. 29(3). 179–187. 490 indexed citations

20.

Asme, et al.. (1994). Advances in Computational Methods in Fluid Dynamics. Infoscience (Ecole Polytechnique Fédérale de Lausanne). 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact